PTGS2 and neoplasm: A study by Xu et al., has predicted that COX-2 inhibitors targeting tumor inflammation and angiogenesis could enhance the activity of conventional anti-angiogenic therapeutics against pre-established metastases and improve the prognosis for patients with COX-2 overexpressing tumors (185).